Protein kinase C

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Retrieved on: 
Monday, April 8, 2024
Transforming growth factor beta, Partnership, Acquisition, Cancer, Protein kinase, Windtree Therapeutics, Lung cancer, Note, Therapy, Protein kinase C, PKC, Skin, Protein kinase inhibitor, Security (finance)

The Company also completed a $1.5 million convertible note bridge financing.

Key Points: 
  • The Company also completed a $1.5 million convertible note bridge financing.
  • The acquired Varian asset platform is a novel, potential high-potency, specific, aPKCi with possible broad use in oncology as well as certain rare malignant diseases.
  • “Completion of the Varian asset acquisition and the bridge financing represents a potentially transformative next step for Windtree.
  • Additional details are available by reading the Company’s Current Report on Form 8-K relating to the Varian asset acquisition and senior convertible note bridge financing, which was filed with the Securities and Exchange Commission on April 8, 2024.

SYNAPS Dx Announces Prestigious Scientific Advisory Board to Guide Strategy and Commercialization of DISCERN™, Only Autopsy-Validated Test for Accurate Diagnosis of Alzheimer's Disease

Retrieved on: 
Wednesday, January 17, 2024
Research, Managed Care, Pharmaceutical, Mental Health, Medical Devices, Genetics, Science, Biotechnology, Neurology, Medical Supplies, Practice Management, Health, DISCERN, Patient, Dementia, Biology, ELISA, Multimedia, Culture, UTMB, Knowledge, Diagnosis, Neuron, Translational neuroscience, Memory, Software-defined, Neurodegenerative disease, Immunotherapy, Fibroblast, Skin, USC, Protein kinase C, SAB, Disease, Michigan State University, FDA, Therapy, Doctor of Philosophy, Inflammation, Master of Science, Brain, Ageing, Physician, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240117576710/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240117576710/en/
    • Alberto J. Espay, MD, MSc, chairman of the SAB, has over 300 published peer-reviewed research articles and 10 books on neurodegenerative diseases.
  • • Giulio Taglialatela, PhD, serves as the vice chair for research of the Department of Neurology and the director of the UTMB Mitchell Center for Neurodegenerative Diseases.
  • “We are honored to partner with such exceptional thought leaders who are shaping the future of brain health and advancing the biology of memory.
  • The AD-biomarker index also composes one of the three assays and tests skin fibroblasts from biopsies to culture to confluency.

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Retrieved on: 
Wednesday, July 19, 2023
Learning, US Food Sovereignty Alliance, Cleveland Clinic, Therapy, Cognitive deficit, Drug discovery, Clinical trial, Deficit spending, Research, Brain, Multiple sclerosis, Remyelination, MS, MRI, Barrow Neurological Institute, Regeneration, Fragile X syndrome, MD, Immune system, Synapse, Protein kinase C, Principal, Magnetic resonance imaging, IND, Memory, Alzheimer's disease, Food, Safety, Disease, Pharmaceutical industry

NEW YORK, July 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it entered into an agreement with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS). Cleveland Clinic will manage the clinical trial's implementation, including an Investigational New Drug (IND) submission to the US Food and Drug Administration and patient enrollment.

Key Points: 
  • Cleveland Clinic will manage the clinical trial's implementation, including an Investigational New Drug (IND) submission to the US Food and Drug Administration and patient enrollment.
  • "Cognitive impairment is a major unmet need in the treatment of people living with MS and we look forward to exploring the potential impact of this investigational drug."
  • Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix, added, "We are moving forward with our clinical development plans for Bryostatin-1 in MS in collaboration with Cleveland Clinic.
  • The planned clinical trial will be held at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis, one of the largest and most comprehensive programs for MS care and research worldwide.

SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer’s Disease Diagnostic Test

Retrieved on: 
Tuesday, August 9, 2022
Biotechnology, Health, Family, Consumer, Other Health, Pharmaceutical, Practice Management, Mental Health, Research, Managed Care, General Health, Science, Women, Seniors, Multimedia, Protein kinase C, Biomarker, Diet, Bradykinin, DISCERN, CEO, Dementia, Diagnosis, Software-defined, Technology, Brain, Cognition, Memory, GIC, Autopsy, Research, Environment, Physician, Patient, Company, PET, Biotechnology, AD, Clinical Laboratory, Phosphorylation, CLIA, Medical imaging

SDx will continue to build and scale its commercialization activities, providing prescribers, payers and patients with a diagnostic test that is an important breakthrough for the AD community.

Key Points: 
  • SDx will continue to build and scale its commercialization activities, providing prescribers, payers and patients with a diagnostic test that is an important breakthrough for the AD community.
  • SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimers disease (AD).
  • The Company offers DISCERN, the first highly accurate, minimally invasive test supporting a clinicians definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia.
  • SYNAPS Dxs laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing.

SYNAPS Dx Highlights Alzheimer’s & Brain Awareness Month in June, Offers First Skin Test for Diagnosing Alzheimer’s Disease

Retrieved on: 
Tuesday, June 7, 2022
Biotechnology, Practice Management, Managed Care, Other Health, Health, Women, Seniors, Pharmaceutical, Mental Health, Family, Consumer, Biomarker, Company, Clinical Laboratory, Cognition, Research, Phosphorylation, Lists of diseases, Dementia, CLIA, CEO, DISCERN, Autopsy, Awareness, American Brain Tumor Association, Brain, Memory, Patient, AD, Risk, Protein kinase C, Bradykinin, Diagnosis, Software-defined, Physician, Alzheimer's disease, Medical imaging, Medical device

Early Alzheimer's diagnosis provides an opportunity to participate in these clinical trials and, ultimately, a better chance of benefiting from treatment.

Key Points: 
  • Early Alzheimer's diagnosis provides an opportunity to participate in these clinical trials and, ultimately, a better chance of benefiting from treatment.
  • SYNAPS Dx is a privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimers disease (AD).
  • The Company offers DISCERN, the first highly accurate, minimally invasive skin test supporting a clinicians definitive diagnosis of AD versus other forms of dementia, even in early disease.
  • SYNAPS Dxs laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing.

Global Diabetic Macular Edema Drug Pipeline Market Research Report 2022: Comprehensive Insights About 65+ Companies and 65+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Diabetes, Inflammation, PKI, BTK, PKC, RVO, II, Population, Central retinal vein occlusion, Survival, Retina, UNITY, Patient, Mergers and acquisitions, Chronic lymphocytic leukemia, Macular edema, Visual acuity, Pharmacokinetics, VEGF, Retinal haemorrhage, SAD, Adult, Intravitreal injection, Cell, Volunteering, Bcl-xL, AMD, Protein kinase C, Diabetic retinopathy, NF-κB, Human, III, IVT, CLL, Technology, Safety, ABC, Kodiak, NDA, Biotechnology, Severe cognitive impairment, Therapy, Protein, Unity Biotechnology, Diabetes, Acquisition, PK, INTEGRAL, PLCG2, DME, Pharmaceutical industry, Vaccine, Meanings of minor planet names: 16001–17000

This ''Diabetic Macular Edema - Pipeline Insight, 2022" report provides comprehensive insights about 65+ companies and 65+ pipeline drugs in Diabetic Macular Edema pipeline landscape.

Key Points: 
  • This ''Diabetic Macular Edema - Pipeline Insight, 2022" report provides comprehensive insights about 65+ companies and 65+ pipeline drugs in Diabetic Macular Edema pipeline landscape.
  • A detailed picture of the Diabetic Macular Edema pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema treatment guidelines.
  • The assessment part of the report embraces, in depth Diabetic Macular Edema commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Diabetic Macular Edema.

SYNAPS Dx Presents at ISPOR Annual Conference, Demonstrates 90% of Physicians Follow Results of DISCERN, First Skin Test for Alzheimer’s Disease

Retrieved on: 
Monday, May 9, 2022
Biotechnology, Practice Management, Managed Care, Health, General Health, Women, Seniors, Pharmaceutical, Mental Health, Family, Consumer, AD, Lists of diseases, MMSE, Brain, Company, Biomarker, Physician, Cognition, Patient, Professional, Syphilis, Diagnosis, Software-defined, Clinical Laboratory, Dementia, Protein kinase C, DISCERN, Disease, Bradykinin, Memory, CLIA, Geriatrics, Conference, CEO, Lyme disease, Research, Autopsy, Phosphorylation, Neurology, Medical imaging

The study relied on a web survey-based conjoint analysis to estimate preferences from a sample of primary care physicians, neurologists and geriatricians.

Key Points: 
  • The study relied on a web survey-based conjoint analysis to estimate preferences from a sample of primary care physicians, neurologists and geriatricians.
  • SYNAPS Dx is a privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimers disease (AD).
  • The Company offers DISCERN, the first highly accurate, minimally invasive skin test supporting a clinicians definitive diagnosis of AD versus other forms of dementia, even in early disease.
  • SYNAPS Dxs laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing.

Aphios Granted US Patent For Combination HIV Latency Nanoparticles Towards an HIV Cure

Retrieved on: 
Tuesday, February 8, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Pandemic, Growth, Patent, Factor X, HIV/AIDS, Bubonic plague, Neurological disorder, Nanoparticle, Protein kinase, Memory, US, HIV, AIDS, HDAC, Elijah Cummings Lower Drug Costs Now Act, Infection, Technology, Conditional sentence, Corporation, ARV, ART, Chromatin, Family, CEO, PKC, Therapy, Supply (economics), Cancer, HIV-1, Drug discovery, Cell, Protein kinase C, COVID-19, Pharmaceutical industry

The Aphios 11,234,932 patent is part of a family of patents for a combination of two Latency Reversal Agents (LRAs) -- a Protein Kinase C (PKC) modulator of the anti-tumor class, ‘Bryoids’ and a Histone Deacetylase (HDAC) inhibitor co-encapsulated in long-circulating pegylated nanoparticles to purge latent HIV from cellular reservoirs. These patents are for the nanoparticles, medications, their manufacturing and uses. The two LRAs act synergistically. Bryostatin-1 activates, via a classical PKC pathway, transcription factors such as NF-κB that binds HIV-1 promoters and regulates their transcription, while the HDAC inhibitors increase histone acetylation, relaxing (opening) chromatin and facilitating the transcription of HIV-1 genes.

Key Points: 
  • Aphios Corporation announced today that it has been granted US Patent No.
  • 11,234,932 for treating HIV latency towards an HIV cure.
  • HIV, however, establishes latent long-term infection in a small pool of memory CD4+ T (immune) and other cells, which contain integrated but transcriptionally silent HIV provirus.
  • There are no commercially available drugs for treating HIV latency and/or curing HIV.

MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema

Retrieved on: 
Friday, November 12, 2021
Biotechnology, Pharmaceutical, Optical, Finance, Health, Diabetes, Professional Services, Clinical Trials, PKC, PK, Safety, Protein kinase C, Lists of diseases, Degenerative disease, PLCG2, MD, CRT, Digital technology, Neuroscience, CEO, Diabetic retinopathy, MBA, Inflammation, CSO, Artificial intelligence, Program, Chronic lymphocytic leukemia, BTK, DME, Trust, VEGF, Ophthalmology, Visual acuity, Doctor of Philosophy, Lymphoid leukemia, Skin, Patient, CLL, Kidney, Retina, Pharmaceutical industry, MS-553, MingSight Pharmaceuticals, Kaitai Capital, MS-553, MINGSIGHT PHARMACEUTICALS, KAITAI CAPITAL

The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME).

Key Points: 
  • The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME).
  • We greatly appreciate the trust and support of our investors, said Kai Zhang, MD, MBA, CEO and Co-founder of MingSight.
  • We look forward to working with Kaitai and our other investors to accelerate the development of this unique compound.
  • MingSight is a clinical stage company focused on developing differentiated, novel therapies for serious diseases including B-cell malignancies, diabetic macular edema, and autoimmune diseases.

Aphios Granted Chinese Patent for Novel Bryoid to Treat Alzheimer’s Disease

Retrieved on: 
Wednesday, November 10, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, PKC, Neurodegeneration, Safety, Protein kinase C, China National Intellectual Property Administration, CEO, HIV, Technology, Method, Cancer, Glaucoma, Drug discovery, Chinese patent medicine, Patent, Pharmaceutical industry

Aphios Corporation today announced that it has been granted Chinese Patent No.

Key Points: 
  • Aphios Corporation today announced that it has been granted Chinese Patent No.
  • 201811111996.8 by China National Intellectual Property Administration on October 26, 2021.
  • The patent entitled, Bryoid Compositions, Methods of Making and Use Thereof, covers novel composition of matter of the novel Bryoid, Bryostatin-23 and use for the treatment of Alzheimers disease and other neurodegenerative diseases, virus latency diseases such as HIV and Herpes, cancers and glaucoma.
  • About Aphios Corporation: Aphios Corporation ( www.aphios.com ) is a green biotechnology company developing enabling technology platforms for improving drug discovery, manufacturing, delivery and safety, and enhanced natural therapeutics for health maintenance and disease prevention, and treatment of Alzheimers disease.